Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution
Abstract
Even for patients who are very stable while receiving i.v. epoprostenol over a long period of time, any
transition to selexipag warrants careful long-term clinical and haemodynamic follow-up because
worsening is likely to occur.
Origin : Publication funded by an institution
Licence : CC BY - Attribution
Licence : CC BY - Attribution